By Mill Chart
Last update: Jun 24, 2024
Growth investors are on the lookout for stocks displaying robust revenue and EPS growth. In this analysis, we'll assess whether HALOZYME THERAPEUTICS INC (NASDAQ:HALO) aligns with growth investing criteria, especially as it consolidates and signals a possible breakout. As always, investors should conduct their own research, but HALOZYME THERAPEUTICS INC has surfaced on our radar for growth with base formation, warranting further examination.
A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:HALO has received a 9 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:HALO has earned a 7 out of 10:
Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:HALO has achieved a 7:
ChartMill also assign a Setup Rating to every stock. With this score it is determined to what extend the stock has been trading in a range in the recent days and weeks. This score also ranges from 0 to 10 and is updated daily. The setup score evaluates various short term technical indicators. NASDAQ:HALO scores a 8 out of 10:
HALO has an excellent technical rating and also presents a decent setup pattern. Prices have been consolidating lately and the volatility has been reduced. There is a resistance zone just above the current price starting at 51.56. Right above this resistance zone may be a good entry point. We notice that large players showed an interest for HALO in the last couple of days, which is a good sign. Very recently a Pocket Pivot signal was observed. This is another positive sign.
More Strong Growth stocks can be found in our Strong Growth screener.
For an up to date full fundamental analysis you can check the fundamental report of HALO
Check the latest full technical report of HALO for a complete technical analysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
54.73
+0.3 (+0.55%)
Find more stocks in the Stock Screener
HALOZYME THERAPEUTICS (NASDAQ:HALO) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the biotech sector for investors seeking affordable growth opportunities.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
HALOZYME THERAPEUTICS (NASDAQ:HALO) is an undervalued biotech stock with strong profitability, financial health, and growth potential, making it a compelling pick for value investors.